Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0R6JV
|
||||
| Former ID |
DIB000702
|
||||
| Drug Name |
CX-1739
|
||||
| Synonyms |
CX-1739 (injectable/AMPAKINE, respiratory depression); CX-717 follow-on compound (AMPAKINE), Cortex Pharmaceuticals; CX-1739 (injectable/AMPAKINE, respiratory depression), Biovail Laboratories; CX-1739 (injectable/AMPAKINE, respiratory depression), Cortex Pharmaceuticals; CX-1739 (injectable/AMPAKINE, respiratory depression), Valeant
|
||||
| Indication | Attention deficit hyperactivity disorder [ICD9: 314; ICD10:F90] | Phase 2 | [548779] | ||
| Company |
Cortex Pharmaceuticals Inc
|
||||
| Target and Pathway | |||||
| Target(s) | Glutamate receptor AMPA subtype | Target Info | Agonist | [531966] | |
| References | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.

